Soini Sirpa
Faculty of Law, Institute for Health and Welfare (THL) and University of Helsinki, Helsinki, Finland,
J Community Genet. 2012 Jan 28;3(2):143-53. doi: 10.1007/s12687-012-0078-0.
Rapid developments of biomedical science have initiated different fora to take stand on the protection of human rights and human dignity. In front of the new genomic era with the completion of the Human Genome Project in 2003, a plethora of instruments addressing human genetic testing emerged, some looking suspiciously like legal acts. The notion of genetic exceptionalism was characteristic to the normative reactions in the legal acts, but it can be questioned how justified this is. Despite the critique on genetic exceptionalism, it is argued that in certain situations detection of a serious genetic anomaly may cause extra anxiety in a person tested, if the knowledge has a great significance also to family members. Regulative needs should depend on the context and purpose of the test. This review examines the legal framework governing the use of genetic tests in the clinical setting in Western Europe. Five countries have enacted genetic specific laws, and three have comprehensive provisions pertaining genetic testing in their biomedical legislation. Central provisions cover informed consent, autonomy and integrity of the person tested, further uses of tests results, quality requirements of the personnel and facilities involved. Moreover, contemporary challenges related to whole genome sequencing, direct-to-consumer genetic tests and insurance are briefly discussed.
生物医学科学的快速发展引发了不同的论坛就人权和人类尊严的保护表明立场。在2003年人类基因组计划完成后的新基因组时代面前,出现了大量涉及人类基因检测的文书,其中一些看起来很像法律行为。基因例外论的概念是法律行为中规范性反应的特征,但这种做法的合理性值得质疑。尽管对基因例外论存在批评,但有人认为,在某些情况下,如果检测出严重的基因异常对受测者来说意义重大,且对其家庭成员也有很大影响,那么这可能会给受测者带来额外的焦虑。监管需求应取决于检测的背景和目的。本综述考察了西欧临床环境中基因检测使用的法律框架。五个国家颁布了基因专项法律,三个国家在其生物医学立法中有关于基因检测的全面规定。核心规定包括知情同意、受测者的自主性和完整性、检测结果的进一步使用、相关人员和设施的质量要求。此外,还简要讨论了与全基因组测序、直接面向消费者的基因检测和保险相关的当代挑战。